Friday, October 2, 2015

7:00 PM – 10:00 PM Welcome Reception

Saturday, October 3, 2015

7:00 AM – 8:00 AM BREAKFAST and Networking

8:00 AM – 8:15 AM Opening Remarks

8:15 AM – 9:00 AM The Case for a NeuroStar TMS Therapy Center

  • Examine how the TMS landscape is evolving to support center models
  • Leveraging Neuronetics partnership for success day one and beyond

9:00 AM – 9:45 AM Keynote: Clinical Application of NeuroStar TMS Therapy

9:45 AM – 10:15 AM The Evolution of NeuroStar Data
Recent progress in NeuroStar TMS Therapy clinical research initiatives

10:15 AM – 10:30 AM BREAK

10:30 AM – 11:15 AM Strategic and Tactical Considerations for Planning a NeuroStar Center

  • Define and examine center ownership models
  • Consider strategy development
  • How to cultivate physician partnership options

11:15 AM – 12:00 AM Operationalizing NeuroStar TMS Therapy in a Center-Model Setting

  • Planning infrastructure
  • Staffing considerations
  • Physician involvement in daily operations
  • Developing a staff training/proctorship program

12:00 PM – 1:00 PM LUNCH and Networking

1:00 PM – 1:45 PM Building Awareness and Outreach in the Center-Model Setting

  • Developing your referral network
  • Increasing awareness through community outreach and advertising

1:45 PM – 2:30 PM Enhancing Your Online Presence with Web Marketing & Social Media

  • Techniques to raise your search engine visibility
  • Ways to engage site visitors
  • An overview of social media platforms
  • Methods for monitoring campaign success

2:30 PM – 3:00 PM BREAK and Networking

3:00 PM – 3:45 PM Reimbursement in the Center Setting

  • Reimbursement best practices in a center (centralized intake, case management and billing)
  • Provider contract negotiations with payers

3:45 PM – 4:30 PM Panel Discussion and Meeting Close

Call 610-981-4110 to register for NeuroStar 360

All trademarks are the property of Neuronetics, Inc.

*NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical trial version of the NeuroStar TMS System, were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05)1

The most common side effect is pain or discomfort at or near the treatment site.2 These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. NeuroStar TMS Therapy is contraindicated in patients with non-removable conductive metal in or near the head.

NeuroStar TMS Therapy is available by prescription only. For full prescribing and safety information, please visit or call Neuronetics Customer Service at 1-877-600-7555.

1) George, MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder A Sham-Controlled Randomized Trial. Arch Gen Psychiatry. 67(5): 507-516.
2) Janicak, PG, et al. (2008) Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Comprehensive Summary of Safety Experience from Acute and Extended Exposure and During Reintroduction Treatment. J Clin Psychiatry, 69(2):222-232.